Clinical trial • Phase I • Immunology|Rare Disease
Clinical trial in C3 glomerulopathy (C3G)
Phase I trial for C3 glomerulopathy (C3G). 58 participants.
Overview
- Trial Therapeutic Area
- Immunology|Rare Disease
- Trial Disease
- C3 glomerulopathy (C3G)
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 23-12-2024
- First CTIS Authorization Date
- 02-06-2025
Trial design
Phase I trial across 15 sites in Austria, Latvia, Sweden and others.
- Target Sample Size
- 58
Eligibility
Recruits 58 Vulnerable population not selected; no specific consent or assent handling described in the record..
- Vulnerable Population
- Vulnerable population not selected; no specific consent or assent handling described in the record.
Recruitment
- Planned Sample Size
- 58
- Recruitment Window Months
- 13
- Consent Approach
- No consent or assent process described in the provided record.
Geography
- Total Number Of Sites
- 15
- Total Number Of Participants
- 58
Austria
- Earliest CTIS Part Ii Submission Date
- 16-04-2025
- Latest Decision Or Authorization Date
- 17-02-2026
- Processing Time Days
- 307
- Number Of Sites
- 1
- Number Of Participants
- 23
Sites
- Site Name
- Medical University Of Vienna
- Department Name
- Universitätsklinik für Klinische Pharmakologie
- Contact Person Name
- Bernd Jilma
- Contact Person Email
- bernd.jilma@meduniwien.ac.at
Latvia
- Earliest CTIS Part Ii Submission Date
- 25-08-2025
- Latest Decision Or Authorization Date
- 12-02-2026
- Processing Time Days
- 171
- Number Of Sites
- 1
- Number Of Participants
- 5
Sites
- Site Name
- Pauls Stradins Clinical University Hospital
- Department Name
- Nephrology
- Contact Person Name
- Aivars Pētersons
- Contact Person Email
- Aivars.Petersons@stradini.lv
Sweden
- Earliest CTIS Part Ii Submission Date
- 28-07-2025
- Latest Decision Or Authorization Date
- 11-02-2026
- Processing Time Days
- 198
- Number Of Sites
- 1
- Number Of Participants
- 2
Sites
- Site Name
- Karolinska University Hospital
- Department Name
- Clinical Pharmacology
- Contact Person Name
- Staffan Rosenborg
- Contact Person Email
- staffan.rosenborg@ki.se
Czechia
- Earliest CTIS Part Ii Submission Date
- 02-08-2025
- Latest Decision Or Authorization Date
- 10-02-2026
- Processing Time Days
- 192
- Number Of Sites
- 1
- Number Of Participants
- 5
Sites
- Site Name
- Fakultni Thomayerova nemocnice
- Department Name
- Clinical Pharmacology Unit.
- Contact Person Name
- Jiří Škopek
- Contact Person Email
- jiri.skopek1@ftn.cz
Netherlands
- Earliest CTIS Part Ii Submission Date
- 29-08-2025
- Latest Decision Or Authorization Date
- 12-02-2026
- Processing Time Days
- 167
- Number Of Sites
- 1
- Number Of Participants
- 2
Sites
- Site Name
- Amsterdam UMC Stichting
- Department Name
- Department of Internal Medicine and Pediatrics
- Contact Person Name
- Marc Hilhorst
- Contact Person Email
- m.l.hilhorst@amsterdamumc.nl
Belgium
- Earliest CTIS Part Ii Submission Date
- 13-08-2025
- Latest Decision Or Authorization Date
- 11-02-2026
- Processing Time Days
- 182
- Number Of Sites
- 1
- Number Of Participants
- 2
Sites
- Site Name
- Cliniques universitaires Saint-Luc
- Department Name
- Rare Kidney Disease Clinic
- Contact Person Name
- Nathalie Demoulin
- Contact Person Email
- nathalie.demoulin@saintluc.uclouvain.be
France
- Earliest CTIS Part Ii Submission Date
- 04-09-2025
- Latest Decision Or Authorization Date
- 09-02-2026
- Processing Time Days
- 158
- Number Of Sites
- 2
- Number Of Participants
- 5
Sites
- Site Name
- Hôpital Européen Georges-Pompidou HEGP
- Department Name
- Service de Néphrologie et Hémodialyse
- Contact Person Name
- Sophie Chauvet
- Contact Person Email
- sophie.chauvet@aphp.fr
- Site Name
- Centre Hospitalier Universitaire De Toulouse
- Department Name
- Service de Néphrologie et Transplantation d’Organes
- Contact Person Name
- Stanislas Faguer
- Contact Person Email
- faguer.s@chu-toulouse.fr
Portugal
- Earliest CTIS Part Ii Submission Date
- 16-06-2025
- Latest Decision Or Authorization Date
- 14-04-2026
- Processing Time Days
- 302
- Number Of Sites
- 1
- Number Of Participants
- 1
Sites
- Site Name
- Hospital Curry Cabral_Centro Hospitalar de Lisboa Central - ULS Sao José
- Department Name
- Nephrology
- Contact Person Name
- Cristina Jorge
- Contact Person Email
- cristina.jorge2@ulssjose.min-saude-pt
Spain
- Earliest CTIS Part Ii Submission Date
- 31-07-2025
- Latest Decision Or Authorization Date
- 16-02-2026
- Processing Time Days
- 200
- Number Of Sites
- 5
- Number Of Participants
- 7
Sites
- Site Name
- Clinica Universidad De Navarra
- Department Name
- Department of Nephrology
- Contact Person Name
- Jose Maria Mora
- Contact Person Email
- jmora@unav.es
- Site Name
- Hospital Universitario Virgen De La Macarena
- Department Name
- Nefrología. Planta 7ª D
- Contact Person Name
- Mercedes Salgueira
- Contact Person Email
- mercedes.salgueira.sspa@juntadeandalucia.es
- Site Name
- University Hospital Virgen Del Rocio S.L.
- Department Name
- Department of Nephrology
- Contact Person Name
- Miguel Ángel Pérez
- Contact Person Email
- miguelangelperezvaldivia@gmail.com
- Site Name
- Fundacio Puigvert
- Department Name
- Department of Nephrology
- Contact Person Name
- Xoana Barros
- Contact Person Email
- xbarros@fundacio-puigvert.es
- Site Name
- Hospital Universitario 12 De Octubre
- Department Name
- Nephrology
- Contact Person Name
- Fernando Caravaca-Fontan
- Contact Person Email
- fcaravacaf@gmail.com
Greece
- Earliest CTIS Part Ii Submission Date
- 08-08-2025
- Latest Decision Or Authorization Date
- 11-03-2026
- Processing Time Days
- 215
- Number Of Sites
- 1
- Number Of Participants
- 1
Sites
- Site Name
- Laiko General Hospital Of Athens
- Department Name
- Clinic of Nephrology and Renal Transplantation
- Contact Person Name
- Smaragdi Marinaki
- Contact Person Email
- smaragdimarinaki@yahoo.com
Lithuania
- Earliest CTIS Part Ii Submission Date
- 22-08-2025
- Latest Decision Or Authorization Date
- 14-04-2026
- Processing Time Days
- 235
- Number Of Sites
- 1
- Number Of Participants
- 5
Sites
- Site Name
- Vilnius University Hospital Santaros Klinikos
- Department Name
- Nephrology
- Contact Person Name
- arius Miglinas
- Contact Person Email
- marius.miglinas@santa.lt
Sponsor
Primary sponsor
- Full Name
- Eleva GmbH
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Germany
Related trials
Other published trials that may interest you.
- DAZODALIBEP for Sjögren's syndrome
- rilzabrutinib for Immune thrombocytopenic purpura | Immune Thrombocytopenia Purpura
- DONIDALORSEN for Hereditary angioedema
- ALLOGENEIC ADIPOCYTE-DERIVED MESENCHYMAL STROMAL CELLS TRANSDUCED WITH A LENTIVIRAL PROVIRUS VECTOR CONTAINING THE HUMAN CXCR4 AND IL-10 GENES for Acute graft-versus-host disease (aGVHD) | Steroid-refractory acute graft-versus-host disease | Ruxolitinib-refractory acute graft-versus-host disease
- RILZABRUTINIB for Immune thrombocytopenia (ITP)|Autoimmune thrombocytopenia|Primary immune thrombocytopenia